Navigation Links
New drug successfully halts fibrosis in animal model of liver disease
Date:8/7/2012

A study published in the online journal Hepatology reports a potential new NADPH oxidase (NOX) inhibitor therapy for liver fibrosis, a scarring process associated with chronic liver disease that can lead to loss of liver function.

"While numerous studies have now demonstrated that advanced liver fibrosis in patients and in experimental rodent models is reversible, there is currently no effective therapy for patients," said principal investigator David A. Brenner, MD, vice chancellor for Health Sciences and dean of the School of Medicine at the University of California, San Diego. "This new study provides important validation of the role of NOX in liver fibrosis, and suggests that a NOX inhibitor could provide an effective treatment for this devastating disease."

Most chronic liver diseases are associated with progressive fibrosis, which is triggered by the loss of liver cells and the activation of inadequate wound healing pathways. In addition, oxidative stress which results from an inappropriate balance between the production and clearance of highly reactive molecules involved in cell signaling called reactive oxidative species (ROS) leads to aberrant tissue repair in the liver.

When the liver is injured for example, through hepatitis or alcohol abuse HSCs are activated to become myofibroblasts, cells which play a crucial role in wound healing and the body's response to inflammation by recruiting immune cells called macrophages to the injury site. This process, triggered by intracellular signalling pathways involving NOX, can result in an abundance of scarring and eventually result in the loss of organ function.

By inhibiting NOX, the researchers theorized that myofibroblast activation and macrophage recruitment could be interrupted, preventing further fibrosis and potentially allowing regression of established fibrosis.

They assessed the effectiveness of treatment with GKT137831 a NOX1/4 inhibitor developed by Genkyotex SA of Geneva, Switzerland in mouse models, and found that treatment with this NOX inhibitor suppressed ROS production, as well as NOX and fibrotic gene expression.

"These data highlight the excellent pharmacological properties of GKT137831 and the broad potential for its use in fibrotic diseases,'' said Patrick Page, chief development officer at Genkyotex and contributor to the study.

According to Brenner, the next steps include a clinical trial with this drug in patients with liver fibrosis.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. CNIO scientists successfully test the first gene therapy against aging-associated decline
2. Ben-Gurion U. researchers successfully test solar desalination system for arid land agriculture
3. Study evaluates use of inhaled saline for young children with cystic fibrosis
4. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
5. GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer
6. Researchers develop a new cell and animal model of inflammatory breast cancer
7. FDA Seeks to Limit Antibiotics in Animal Feed
8. Animals More Interesting to Kids Than Toys, Study Shows
9. Raucous Music May Tap Into Your Inner Animal
10. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
11. Woodbridge Animal Hospital Unleashes New Pet Care Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Sanford Health’s work ... A group of researchers and leaders from Sanford Health were selected to participate ... Its Cultural Impact ” and receive the 2016 Pontifical Key Innovation Award at ...
(Date:4/28/2016)... CA (PRWEB) , ... April 28, 2016 , ... La ... currently number one in Central America and is looking to grow their market share ... for such an exceptional brand as La Sirena Foods and indirectly with ...
(Date:4/28/2016)... ... 28, 2016 , ... Head Over Heels Athletic Arts’ gymnast, Brooklyn Varize, has ... be held at the University of Montana on April 28-May 1. Varize will compete ... , In order to qualify, Varize needed to place top seven all-around in her ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... a new CDISC standard, Clinical Trial Registry (CTR) XML. Clinical trial registries ... will make it possible to build applications that generate submissions for multiple, ...
(Date:4/28/2016)... ... 28, 2016 , ... Cosmetic Town, an online plastic surgery community, announces the ... was recently revamped and upgraded to allow even more interaction between doctors and patients ... , According to the senior editor of Cosmetic Town, “We are excited that our ...
Breaking Medicine News(10 mins):
(Date:4/26/2016)... , April 26, 2016 Hill-Rom Holdings, Inc. ... a management presentation at the Deutsche Bank 41 st ... 2:50 p.m. EDT. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas . ... hour after conclusion of the live event and accessible at ...
(Date:4/26/2016)... DUBLIN , April 26, 2016 ... "Financial Assessment and Credit Risk Analysis of the Biological ... This comprehensive report analyzes the financial assessment ... China . The report provides readers ... key topics all market participants should be aware of. ...
(Date:4/26/2016)... April 26, 2016 ... 2016;9(1):16-20 DOI: http://doi.org/10.17925/USOR.2016.09.01.16 ... Published recently in US Ophthalmic Review, ... Davidson discusses how laser cataract surgery ... cataract surgery: the laser fragments the lens ...
Breaking Medicine Technology: